NeutralLOW severityHealthcare & Pharma2d ago

Jefferies reiterates Summit Therapeutics stock rating after FDA setback

Jefferies reiterates Summit Therapeutics stock rating after FDA setback — $SMMT one-month chart
$SMMT daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

Summit Therapeutics ($SMMT) closed at $14.15, down 6.14%, near the lower end of its 52-week range. The stock is trading at 12% of its range, with little recent coverage beyond a single neutral note in the last week. The Health Care sector shows calm, but attention to $SMMT has been brief and balanced.

Written by Wook AI Nov 15, 1:31 PM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about SMMT. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · summit therapeuticsEvent risk Low

Nothing reported about summit therapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 121% a year
Now $10.67Week $8.85–$12.49 (±17.1%)Month $6.93–$14.41 (±35.0%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: In healthcare, timing is everything: trial results, FDA updates, and pricing shifts are the main drivers of stock movement.
  • How the stock is trading: $SMMT -9.48% in the latest session.
  • Timing: It was published over the weekend. The change shown is Friday's, and Monday is the first session that could react. Market holidays are not detected.

Where the stock stands

Summit Therapeutics ($SMMT) dropped 9.48% to $10.70 in the latest session. Over the past month it is down 31.5%. It now sits 63% under the 52-week high of $29.23 and 1.6% above the year's low of $10.53, close to the bottom of its range. The year's high was 2.8 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 4, 2026), $SMMT lost $208.4M over the quarter to Sep 30, 2026. Operations used $423.2M of cash over the nine months to Sep 30, 2026 — about $47.2M a month — against $150.8M in cash on Sep 30, 2026. At that pace the cash covers about 3 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $128.2M against $150.8M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 16, 1 day after this story; it is $SMMT's own account and the first thing to read. Figures are as filed with the SEC; the $SMMT page has the full statements.

How much coverage it is getting

This is one of 4 stories on Summit Therapeutics in Wook's last 30 days of coverage, including 3 this week. That is well above its usual pace: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 2 neutral and 2 bearish. This one reads neutral, like most of them. This is the only one from Investing.com; the rest came from other outlets.

The bigger picture

Healthcare moves on the calendar — trial outcomes, FDA decisions, and pricing rules. One drug's result can shift a company's fate; a policy change can ripple across the entire sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.

What to watch next

For the company's side of it, read its latest SEC filings on the $SMMT page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $SMMT: its distance from the high, its last report, or how coverage has changed.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on November 15, 2026. $SMMT has moved +2.20% ($10.47 to $10.70). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy